Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
New insights into COVID-19 infectiousness
Fri August 19th - British researchers have unveiled the first real-world study to estimate how long people are infectious with mild COVID-19. More
Gene variant that protects against heart disease
Fri August 19th - A gene variant has been identified that helps to protect against heart diseases. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

COVID-19 vaccines may protect against variants

Friday March 19th 2021

Existing COVID-19 vaccines are likely to protect against the Brazilian coronavirus variant, scientists at the University of Oxford, UK, have reported.

Pre-print data suggest that natural- and vaccine-induced antibodies can still neutralise variants that are circulating from South Africa, Brazil and elsewhere, but at lower levels. Their findings also suggest the P1 ‘Brazilian’ strain may be less resistant to these antibodies than first feared.

Lead study scientist Professor Gavin Screaton said: “This study extends our understanding the role of changes in the spike protein in escape from the human immune response, measured as neutralising antibody levels. The results suggest that P1 might be less resistant to vaccine and convalescent immune responses than B.1.351, and similar to B.1.1.7.”

In the pre-print publication, available on bioRxi, the authors report on the neutralisation of these strains when using blood samples from people who have developed natural antibodies following a COVID-19 infection and from those with antibodies generated from the Oxford-AstraZeneca and Pfizer-BioNTech vaccines.

The data show a nearly three-fold reduction in the level of virus neutralisation by the antibodies generated by the vaccines for the B.1.1.7 (Kent) and P.1 (Brazil) variants when compared to the original “Victoria” strain, and a nine-fold and 7.6-fold reduction respectively against the B.1.351 (South Africa) strain.

Professor Andrew Pollard, chief investigation on the Oxford University vaccine trial, said: “These further efforts to investigate the relationship between changes in the virus and human immunity provide new insights that help us be prepared to respond to further challenges to our health from the pandemic virus, if we need to do so.”

The authors write that because P.1 and B.1.351 contain similar changes in the receptor binding domain, it was assumed that the neutralising antibodies would be similarly affected, which would mean vaccination is likely to provide some protection against P.1.

The drop in vaccine efficacy against mild to moderate disease against B.1.351 is likely a reflection of the mutations occurring outside the receptor binding domain, they add.

They conclude that developing vaccine constructs to B.1.351 should be the greatest priority for vaccine developers globally.

* More than 75% of over-70s in England now have antibodies against COVID-19, highlighting the success of the vaccine programme, Public Health England reported yesterday.

Just 5.6% of the population had antibodies from natural infection, researchers found.

The agency said the findings suggested that most recipients had a strong response to their first dose of vaccine.

Its head of immunisation Dr Mary Ramsey said: “The latest data continue to show that both vaccines in use in the UK are still providing really good levels of protection against COVID-19. As well as reducing cases, if vaccinated people catch COVID-19, they are less likely to get serious illness and die.”

• The pandemic reduced projected life expectancy for men in England by more than a year, according to a new analysis.

The reduction for men was 1.3 years and for women 0.9 years, Public Health England said.

Dejnirattisai W, Zhou D, Supasa P et al. Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2. bioRxiv 19 March 2021; doi:


Tags: Flu & Viruses | South America | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)